		_						
					ATTORNEY DOCKET APPLICATION NO.			
INFORMATION DISCLOSURE STATEMENT								
(37 C.F.R. 1.56, 1.97, and 1.98)								
01, 50					23164-10	001	08/853,870	
(§)					APPLICANT(S)			
FEB 0 1 1999 (E)					Michael G. Tovey			
SHEET 1 OF 1					FILING DATE		GROUP	
TO ADEMARK					May 9, 19	997	1614	
SHEET 1 OF 1 FILING DATE May 9, 1997 1614 U.S. PATENT DOCUMENTS								
† EX'R * U.S. CLASS/ FILING DAT								
INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME SUBCLASS				(If appropriate)
-								
	<u> </u>							
			<u> </u>					
FOREIGN PATENT DOCUMENTS								
† EX'R	*							TRANSLATION
INITIAL	REF. #							(YES/NO)
							,	
			<u> </u>					
OTHER DOCUMENTS								
† EX'R INIŢIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)						
A								
01	W	Kaido, T.J., "Interanasal administration of IFN-α/β inhibits the development of visceral tumor metastases,"						
V		Journal of Interferon and Cytokine Research, 17:31-36 (1997).						
$\mathcal{O}(\mathcal{N})$	Х	Yoshino, S., "The preventive effect of oral administration of Type 1 interferon on collagen-induced arthritis in rats," <i>Experimental and Molecular Pathology</i> , 62:123-130 (1995).						
WI		artinus ni rats, Experimental and Molecular Fathology, 02.123-130 (1995).						
•								
,								
•								
EXAMINER'S SIGNATURE \ DATE CONSIDERED \								
	/ W/	$VV \vee$	/		1 Whi	2001		
+ EVARAL	NIED. AV.	al if reference is consider	rod whether or ===	citation in in	1 1 1		ab citation if not in	
† EXAMINER: /Natial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in								